Log in to save to my catalogue

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8357629

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

The Ad26.COV2.S vaccine
1

3
has demonstrated clinical efficacy against symptomatic COVID-19, including against the B.1.351 variant that is partially resistant to neutralizing antibodies
1
. However, the immunogenicity of this vaccine in humans against SARS-CoV-2 variants of concern remains unclear. Here we report humoral and cel...

Alternative Titles

Full title

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8357629

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8357629

Other Identifiers

ISSN

0028-0836,1476-4687

E-ISSN

1476-4687

DOI

10.1038/s41586-021-03681-2

How to access this item